Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Offidani, Massimo  [Clear All Filters]
Journal Article
Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MTeresa, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, et al. Autologous Transplantation and Maintenance Therapy in Multiple Myeloma. N Engl J Med. 2014;371(10):895-905.
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2015.
Bringhen S, Petrucci MTeresa, Larocca A, Conticello C, Rossi D, Magarotto V, Musto P, Boccadifuoco L, Offidani M, Omedé P, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014.
Morè S, Corvatta L, Maracci L, Costantini B, Olivieri A, Offidani M. Developments in consolidation and maintenance strategies in post-remission multiple myeloma. Expert Rev Hematol. 2020:1-12.
Capelli D, Chiarucci M, Poloni A, Saraceni F, Mancini G, Trappolini S, Troiani E, Montanari M, Scortechini I, Offidani M, et al. Mobilization-Driven Post-Consolidation Therapy in 55 Elderly Aml Patients: Feasibility and Efficacy of Asct Vs Low Dose Gemtuzumab-Ozogamicin. Biol Blood Marrow Transplant. 2014.
Bringhen S, Milan A, D'Agostino M, Ferri C, Wäsch R, Gay F, Larocca A, Offidani M, Zweegman S, Terpos E, et al. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A Consensus Paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. J Intern Med. 2019.